Last Updated: May 5, 2026

DOBUTREX Drug Patent Profile

✉ Email this page to a colleague

Which patents cover Dobutrex, and when can generic versions of Dobutrex launch?

Dobutrex is a drug marketed by Lilly and is included in one NDA.

The generic ingredient in DOBUTREX is dobutamine hydrochloride. There are fourteen drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the dobutamine hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Dobutrex

A generic version of DOBUTREX was approved as dobutamine hydrochloride by HOSPIRA on November 29^th, 1993.

Start Trial

AI Deep Research

Questions you can ask:

What is the 5 year forecast for DOBUTREX?
What are the global sales for DOBUTREX?
What is Average Wholesale Price for DOBUTREX?

Summary for DOBUTREX

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for DOBUTREX

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Lilly	DOBUTREX	dobutamine hydrochloride	INJECTABLE;INJECTION	017820-002	Approved Prior to Jan 1, 1982		DISCN	Yes	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

International Patents for DOBUTREX

See the table below for patents covering DOBUTREX around the world.

Subscribe to access the full database, or Start Trial
Country	Patent Number	Title	Estimated Expiration
Japan	S5825656		⤷ Start Trial
Czechoslovakia	190406	PROCESS FOR PREPARING DERIVATIVES OF DOPAMINE	⤷ Start Trial
Australia	472734		⤷ Start Trial
United Kingdom	1392674		⤷ Start Trial
Netherlands	174459		⤷ Start Trial
Denmark	142750		⤷ Start Trial
>Country	>Patent Number	>Title	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.